Benefits of Adjunct Modafinil in an Open-Label, Pilot Study in Patients With Schizophrenia
Authors:
- Murray H. RosenthalMRMurray H. Rosenthal
- Sharon L. BryantSBSharon L. Bryant
- 1 January 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 27 (1) , 38-43
Abstract
Patients with schizophrenia experience cognitive impairments associated with hypofunctioning of the frontal cortex. Modafinil, a novel wake-promoting agent, works through the sleep–wake centers of the brain to activate the cortex. This 4-week, open-label, pilot study evaluated adjunct modafinil in patients with schizophrenia or schizoaffective disorder. Eleven patients received once-daily oral doses of modafinil (100 mg/day, days 1–14; 100 or 200 mg/day, days 15–28) in addition to antipsychotic therapy. Modafinil significantly improved patients' global functioning as assessed by a blinded clinician (week 2, P = 0.026; week 4, P = 0.012) and the investigator (week 3, P = 0.035). Modafinil significantly improved overall clinical condition, with 64% and 82% of patients rated as clinically improved at week 4 by a blinded clinician and the investigator respectively. Eighty-nine percent of patients considered themselves to be clinically improved. Modafinil significantly improved fatigue (P = 0.025, week 3) and tended to improve cognitive functioning scores. Control of positive symptoms was well maintained. Treatment-emergent adverse events included dry mouth (n = 2) and hallucinations (n = 2). One patient discontinued the study because of hallucinations that were considered to be possibly related to inadequate antipsychotic therapy. Although preliminary, these results suggest modafinil may be an effective and well-tolerated adjunct treatment that improves global functioning and clinical condition, and reduces fatigue in patients with schizophrenia or schizoaffective disorder. Additional controlled studies are warranted.Keywords
This publication has 51 references indexed in Scilit:
- A Prospective Trial of Modafinil as an Adjunctive Treatment of Major DepressionJournal of Clinical Psychopharmacology, 2004
- Adjunct Modafinil for the Short-Term Treatment of Fatigue and Sleepiness in Patients With Major Depressive DisorderThe Journal of Clinical Psychiatry, 2003
- Efficacy and safety of modafinil (Provigil(R)) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 studyJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Negative Symptoms of Schizophrenia Are Improved by Paroxetine Added to NeurolepticsThe Journal of Clinical Psychiatry, 2001
- A Double-blind Placebo-controlled Case Study of the Use of Donepezil to Improve Cognition in a Schizoaffective Disorder Patient: Functional MRI Correlates.Neurocase, 2001
- Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsySleep Medicine, 2000
- Schizophrenia and cognitive functionCurrent Opinion in Neurobiology, 2000
- Self‐monitoring cognitive performance during sleep deprivation: effects of modafinil, d‐amphetamine and placeboJournal of Sleep Research, 1997
- Modafinil, d‐amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperatureJournal of Sleep Research, 1995
- Disrupted Sleep-Wake Rhythm and Performance: Advantages of ModafinilMilitary Psychology, 1995